Welcome to chemicalbook!
400-158-6606
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

ChemicalBook > Product Catalogue >API >Antineoplastic agents >Tinib Antineoplastic drugs >Gefitinib

Gefitinib

Gefitinib Structure
  • ₹4200 - ₹45778.93
  • Product name: Gefitinib
  • CAS: 184475-35-2
  • MF: C22H24ClFN4O3
  • MW: 446.9
  • EINECS:643-034-7
  • MDL Number:MFCD04307832
  • Synonyms:N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine Gefitinib;Gefitinib, >=99%;GEFITINIB RELATED COMPOUND;Gefitinib N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine;GEFITINIB;n-(3-chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine;ZD 1839;4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-
4 prices
Selected condition:

Brand

  • TCI Chemicals (India)
  • Sigma-Aldrich(India)

Package

  • 10MG
  • 50MG
  • 1G
  • 5G
  • ManufacturerTCI Chemicals (India)
  • Product numberG0546
  • Product descriptionGefitinib
  • Packaging1G
  • Price₹4200
  • Updated2022-05-26
  • Buy
  • ManufacturerTCI Chemicals (India)
  • Product numberG0546
  • Product descriptionGefitinib
  • Packaging5G
  • Price₹11200
  • Updated2022-05-26
  • Buy
  • ManufacturerSigma-Aldrich(India)
  • Product numberSML1657
  • Product descriptionGefitinib ≥98% (HPLC)
  • Packaging10MG
  • Price₹11355.43
  • Updated2022-06-14
  • Buy
  • ManufacturerSigma-Aldrich(India)
  • Product numberSML1657
  • Product descriptionGefitinib ≥98% (HPLC)
  • Packaging50MG
  • Price₹45778.93
  • Updated2022-06-14
  • Buy
Manufacturer Product number Product description Packaging Price Updated Buy
TCI Chemicals (India) G0546 Gefitinib 1G ₹4200 2022-05-26 Buy
TCI Chemicals (India) G0546 Gefitinib 5G ₹11200 2022-05-26 Buy
Sigma-Aldrich(India) SML1657 Gefitinib ≥98% (HPLC) 10MG ₹11355.43 2022-06-14 Buy
Sigma-Aldrich(India) SML1657 Gefitinib ≥98% (HPLC) 50MG ₹45778.93 2022-06-14 Buy

Properties

Melting point :119-1200C
Boiling point :586.8±50.0 °C(Predicted)
Density :1.322±0.06 g/cm3(Predicted)
storage temp. :room temp
solubility :Soluble in DMSO (up to 40 mg/ml) or in Ethanol (up to 4 mg/ml).
pka :7.00±0.10(Predicted)
form :powder
color :white to beige
Stability :Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 1 month.
CAS DataBase Reference :184475-35-2(CAS DataBase Reference)

Safety Information

Symbol(GHS): GHS hazard pictograms
Signal word: Warning
Hazard statements:
Code Hazard statements Hazard class Category Signal word Pictogram P-Codes
H302 Harmful if swallowed Acute toxicity,oral Category 4 Warning GHS hazard pictograms P264, P270, P301+P312, P330, P501
H315 Causes skin irritation Skin corrosion/irritation Category 2 Warning GHS hazard pictograms P264, P280, P302+P352, P321,P332+P313, P362
H319 Causes serious eye irritation Serious eye damage/eye irritation Category 2A Warning GHS hazard pictograms P264, P280, P305+P351+P338,P337+P313P
H335 May cause respiratory irritation Specific target organ toxicity, single exposure;Respiratory tract irritation Category 3 Warning GHS hazard pictograms
Precautionary statements:
P305+P351+P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

Description

Overactivity of the epidermal growth factor receptor-associated tyrosine kinase (EGFR-TK) has been associated with a number of cancers and thus TK inhibitors could be potential therapeutic agents to prevent malignant growth. Gefitinib is a selective EGFR-TK inhibitor that blocks the growth of GEO colon cancer, ZR-75-1 and MCF-10A Ha-ras breast cancer, and OVCAR-3 ovarian cancer cell lines with IC50s ranging between 0.2-0.4 μM. By interfering with the intracellular kinase domain, gefitinib prevents EGFR autophosphorylation and prevents downstream signal transduction. Gefitinib has been used to treat advanced (or recurrent) non-small cell lung cancer. However, the FDA retracted its general approval for this compound (Iressa?) when a phase III trial failed to demonstrate an overall survival benefit. Gefitinib appears to be most efficacious in treating certain EGFR gene mutations that are prevalent in Asian populations.

Related product price